ArticlePakistan journal of medical sciences2025
Risk factors of epilepsy recurrence in patients with post-stroke epilepsy.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Role of Blood-Brain Barrier Disruption in Epilepsy: Mechanisms and Consequences.Neurology international · 2025Review
- Association between atherogenic index of plasma and post-stroke epilepsy within one year in patients with acute ischemic stroke: a retrospective cohort study.Frontiers in neurologyArticle
- The progress in predictive modeling of post-stroke epilepsy.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the risk factors for epilepsy recurrence in patients with post-stroke epilepsy (PSE), and to determine the optimal timing of anti-epileptic drug administration. Methods: This retrospective study collected clinical data from 90 patients with post-stroke epilepsy (PSE) admitted to Baoding Third Central Hospital from February 2021 to December 2023. Patients were grouped based on epilepsy recurrence. Baseline data, including lesion characteristics, blood homocysteine levels, the National Institute of Health Stroke Scale (NIHSS) scores, and anti-epileptic drug therapy treatment effects, were compared between the recurrent and non-recurrent groups. Logistic analysis was done to determine the risk factors for epilepsy recurrence in patients with PSE. Results: Logistic analysis confirmed that stroke lesion located in the cortex, lesion size ≥ 3 cm, post-stroke late seizure, intracerebral hemorrhage (ICH), blood leakage into the surrounding infarcted tissue, hyperhomocysteinemia (HHcy), and NIHSS scores of ≥ 15 are risk factors for epilepsy recurrence in patients with PSE (P < 0.05). In the recurrent group, a statistically significant difference in treatment effect was found among patients who received anti-epileptic drugs at different time points (P < 0.05). The total efficacy was higher in the early-onset treated (90.91%), early-onset untreated (85.71%), and late-onset treated (80.00%) groups than in the late-onset untreated group (40.00%). In addition, the total effectiveness differed significantly between the early-onset treated and late-onset untreated groups (P < 0.05). Conclusion: Lesion location and size, timing of epileptic seizures, ICH, hemorrhagic transformation, HHcy, and NIHSS scores were identified as risk factors for epilepsy recurrence in patients with PSE. Although early-onset PSE does not require early anti-epileptic treatment, timely treatment should be administered in late-onset cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.